Diabetes Metab J.  2014 Aug;38(4):252-260. 10.4093/dmj.2014.38.4.252.

Diabetic Kidney Disease: From Epidemiology to Clinical Perspectives

Affiliations
  • 1Division of Nephrology, Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea. cheolwhee@hanmail.net

Abstract

With worldwide epidemic of diabetes mellitus, diabetic nephropathy which is one of the major causes of microvascular complication has become a serious concern in Korea as well as the rest of the world. In view of its significance, there is an urgent and paramount need for proper managements that could either deter or slow the progression of diabetic nephropathy. Despite advances in care, ever increasing number of patients suffering from diabetic kidney disease and from end-stage renal disease implies that the current management is not adequate in many aspects. The reasons for these inadequacies compromise lack of early diagnosis, failure to intervene with timely and aggressive manner, and lack of understanding on the kind of interventions required. Another issue equally important for the adequate care of patients with diabetic nephropathy is an understanding of past, present and future epidemiology of diabetic nephropathy which serves, especially in Korea, as a material determining standard diagnosis and treatment and a national health-policy decision.

Keyword

Cardiovascular disorder; Diabetic nephropathies; Renal insufficiency, chronic; Renal replacement therapy

MeSH Terms

Diabetes Mellitus
Diabetic Nephropathies*
Diagnosis
Early Diagnosis
Epidemiology*
Humans
Kidney Failure, Chronic
Korea
Renal Insufficiency, Chronic
Renal Replacement Therapy

Figure

  • Fig. 1 The prevalence of chronic kidney disease (CKD) in Korea, Japan, China, USA, and Australia in 2008.

  • Fig. 2 The prevalence (A) and incidence (B) of end-stage renal disease (ESRD) from 1986 to 2012 among Korean adults from Insan Memorial Dialysis Registry, 2012 [6]. (C) The prevalence of ESRD in various countries including Korea, Japan, China, USA, and Australia. p.m.p., per million people.

  • Fig. 3 (A) Four major causes of end-stage renal disease (ESRD) in Korean adult patients who initiated renal replacement therapy each year among Korean adults from Insan Memorial Dialysis Registry, 2012 [6]. (B) The incidence of diabetic nephropathy (DN) as a cause of ESRD in various countries including Korea, Japan, China, USA, and Australia in 2011. HBP, hypertensive nephropathy; CGN, chronic glomerulonephritis; CD, cystic disease.


Cited by  2 articles

Predictive Factors for Efficacy of AST-120 Treatment in Diabetic Nephropathy: a Prospective Single-Arm, Open-Label, Multi-Center Study
You-Cheol Hwang, Se Won Kim, Kyu Yeon Hur, Bong-Soo Cha, In Joo Kim, Tae Sun Park, Sei Hyun Baik, Kun Ho Yoon, Kwan Woo Lee, In Kyu Lee, Moon-Kyu Lee
J Korean Med Sci. 2019;34(15):.    doi: 10.3346/jkms.2019.34.e117.

Glycemic Management of Patients Undergoing Dialysis
Mi-Kyung Kim
J Korean Diabetes. 2016;17(3):164-167.    doi: 10.4093/jkd.2016.17.3.164.


Reference

1. Hunsicker LG. The consequences and costs of chronic kidney disease before ESRD. J Am Soc Nephrol. 2004; 15:1363–1364.
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351:1296–1305.
3. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005; 16:489–495.
4. Madan P, Kalra OP, Agarwal S, Tandon OP. Cognitive impairment in chronic kidney disease. Nephrol Dial Transplant. 2007; 22:440–444.
5. Chin HJ, Song YR, Lee JJ, Lee SB, Kim KW, Na KY, Kim S, Chae DW. Moderately decreased renal function negatively affects the health-related quality of life among the elderly Korean population: a population-based study. Nephrol Dial Transplant. 2008; 23:2810–2817.
6. Jin DC, Han JS. Renal replacement therapy in Korea, 2012. Kidney Res Clin Pract. 2014; 33:9–18.
7. United States Renal Data System: USRDS Annual Data Report. National Institute of Diabetes and Digestive and Kidney Diseases;2013. updated 2014 May 1. Available from: www.usrds.org.
8. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of chronic kidney disease in the United States. JAMA. 2007; 298:2038–2047.
9. Chadban SJ, Briganti EM, Kerr PG, Dunstan DW, Welborn TA, Zimmet PZ, Atkins RC. Prevalence of kidney damage in Australian adults: the AusDiab kidney study. J Am Soc Nephrol. 2003; 14:7 Suppl 2. S131–S138.
10. Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S, Ura N, Kiyohara Y, Moriyama T, Ando Y, Fujimoto S, Konta T, Yokoyama H, Makino H, Hishida A, Matsuo S. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol. 2009; 13:621–630.
11. Zhang L, Zhang P, Wang F, Zuo L, Zhou Y, Shi Y, Li G, Jiao S, Liu Z, Liang W, Wang H. Prevalence and factors associated with CKD: a population study from Beijing. Am J Kidney Dis. 2008; 51:373–384.
12. Nagata M, Ninomiya T, Doi Y, Yonemoto K, Kubo M, Hata J, Tsuruya K, Iida M, Kiyohara Y. Trends in the prevalence of chronic kidney disease and its risk factors in a general Japanese population: the Hisayama Study. Nephrol Dial Transplant. 2010; 25:2557–2564.
13. Chin HJ, Ahn JM, Na KY, Chae DW, Lee TW, Heo NJ, Kim S. The effect of the World Kidney Day campaign on the awareness of chronic kidney disease and the status of risk factors for cardiovascular disease and renal progression. Nephrol Dial Transplant. 2010; 25:413–419.
14. Kang HT, Lee J, Linton JA, Park BJ, Lee YJ. Trends in the prevalence of chronic kidney disease in Korean adults: the Korean National Health and Nutrition Examination Survey from 1998 to 2009. Nephrol Dial Transplant. 2013; 28:927–936.
15. Ahn JH, Yu JH, Ko SH, Kwon HS, Kim DJ, Kim JH, Kim CS, Song KH, Won JC, Lim S, Choi SH, Han K, Cha BY, Kim NH. Taskforce Team of Diabetes Fact Sheet of the Korean Diabetes Association. Prevalence and determinants of diabetic nephropathy in Korea: Korea national health and nutrition examination survey. Diabetes Metab J. 2014; 38:109–119.
16. Chong YB, Keng TC, Tan LP, Ng KP, Kong WY, Wong CM, Cheah PL, Looi LM, Tan SY. Clinical predictors of non-diabetic renal disease and role of renal biopsy in diabetic patients with renal involvement: a single centre review. Ren Fail. 2012; 34:323–328.
17. Villar E, Polkinghorne KR, Chang SH, Chadban SJ, McDonald SP. Effect of type 2 diabetes on mortality risk associated with end-stage kidney disease. Diabetologia. 2009; 52:2536–2541.
18. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005; 28:164–176.
19. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med. 1999; 341:1127–1133.
20. Young BA, Katon WJ, Von Korff M, Simon GE, Lin EH, Ciechanowski PS, Bush T, Oliver M, Ludman EJ, Boyko EJ. Racial and ethnic differences in microalbuminuria prevalence in a diabetes population: the pathways study. J Am Soc Nephrol. 2005; 16:219–228.
21. Parving HH, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG. DEMAND investigators. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int. 2006; 69:2057–2063.
22. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27:1047–1053.
23. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang YH, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M. Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011; 378:31–40.
24. Centers for Disease Control and Prevention: Diabetes report card 2012: national and state profile of diabetes and its complications. Updated 2013 Apr 3. Available from: http://www.cdc.gov/diabetes/pubs/reportcard.htm.
25. Jeon JY, Ko SH, Kwon HS, Kim NH, Kim JH, Kim CS, Song KH, Won JC, Lim S, Choi SH, Jang MJ, Kim Y, Oh K, Kim DJ, Cha BY. Taskforce Team of Diabetes Fact Sheet of the Korean Diabetes Association. Prevalence of diabetes and prediabetes according to fasting plasma glucose and HbA1c. Diabetes Metab J. 2013; 37:349–357.
26. Jia W, Gao X, Pang C, Hou X, Bao Y, Liu W, Wang W, Zuo Y, Gu H, Xiang K. Prevalence and risk factors of albuminuria and chronic kidney disease in Chinese population with type 2 diabetes and impaired glucose regulation: Shanghai diabetic complications study (SHDCS). Nephrol Dial Transplant. 2009; 24:3724–3731.
27. Lee KU, Park JY, Kim SW, Lee MH, Kim GS, Park SK, Park JS. Prevalence and associated features of albuminuria in Koreans with NIDDM. Diabetes Care. 1995; 18:793–799.
28. Yang CW, Park JT, Kim YS, Kim YL, Lee YS, Oh YS, Kang SW. Prevalence of diabetic nephropathy in primary care type 2 diabetic patients with hypertension: data from the Korean Epidemiology Study on Hypertension III (KEY III study). Nephrol Dial Transplant. 2011; 26:3249–3255.
29. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011; 305:2532–2539.
30. Chen W, Chen W, Wang H, Dong X, Liu Q, Mao H, Tan J, Lin J, Zhou F, Luo N, He H, Johnson RJ, Zhou SF, Yu X. Prevalence and risk factors associated with chronic kidney disease in an adult population from southern China. Nephrol Dial Transplant. 2009; 24:1205–1212.
31. Yokoyama H, Sone H, Oishi M, Kawai K, Fukumoto Y, Kobayashi M. Japan Diabetes Clinical Data Management Study Group. Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes Clinical Data Management study (JDDM15). Nephrol Dial Transplant. 2009; 24:1212–1219.
32. Stanton RC. Clinical challenges in diagnosis and management of diabetic kidney disease. Am J Kidney Dis. 2014; 63:2 Suppl 2. S3–S21.
33. Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA. 2003; 289:3273–3277.
34. Mauer SM, Chavers BM, Steffes MW. Should there be an expanded role for kidney biopsy in the management of patients with type I diabetes? Am J Kidney Dis. 1990; 16:96–100.
35. Mak SK, Gwi E, Chan KW, Wong PN, Lo KY, Lee KF, Wong AK. Clinical predictors of non-diabetic renal disease in patients with non-insulin dependent diabetes mellitus. Nephrol Dial Transplant. 1997; 12:2588–2591.
36. Tone A, Shikata K, Matsuda M, Usui H, Okada S, Ogawa D, Wada J, Makino H. Clinical features of non-diabetic renal diseases in patients with type 2 diabetes. Diabetes Res Clin Pract. 2005; 69:237–242.
37. Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes. 2000; 49:1399–1408.
38. Lin YL, Peng SJ, Ferng SH, Tzen CY, Yang CS. Clinical indicators which necessitate renal biopsy in type 2 diabetes mellitus patients with renal disease. Int J Clin Pract. 2009; 63:1167–1176.
39. Wong TY, Choi PC, Szeto CC, To KF, Tang NL, Chan AW, Li PK, Lai FM. Renal outcome in type 2 diabetic patients with or without coexisting nondiabetic nephropathies. Diabetes Care. 2002; 25:900–905.
40. Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Herzog C, Ishani A, Johansen K, Kasiske B, Kutner N, Liu J, St Peter W, Ding S, Guo H, Kats A, Lamb K, Li S, Li S, Roberts T, Skeans M, Snyder J, Solid C, Thompson B, Weinhandl E, Xiong H, Yusuf A, Zaun D, Arko C, Chen SC, Daniels F, Ebben J, Frazier E, Hanzlik C, Johnson R, Sheets D, Wang X, Forrest B, Constantini E, Everson S, Eggers P, Agodoa L. US renal data system 2012 annual data report. Am J Kidney Dis. 2013; 61:1 Suppl 1. A7e1–e476.
41. Navaneethan SD, Nigwekar S, Sengodan M, Anand E, Kadam S, Jeevanantham V, Grieff M, Choudhry W. Referral to nephrologists for chronic kidney disease care: is non-diabetic kidney disease ignored? Nephron Clin Pract. 2007; 106:c113–c118.
42. Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, de Boer IH. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013; 24:302–308.
43. Jude EB, Anderson SG, Cruickshank JK, Srivatsa A, Tentolouris N, Chandrasekaran R, Gokal R, Boulton AJ. Natural history and prognostic factors of diabetic nephropathy in type 2 diabetes. QJM. 2002; 95:371–377.
44. Muntner P, Bowling CB, Gao L, Rizk D, Judd S, Tanner RM, McClellan W, Warnock DG. Age-specific association of reduced estimated glomerular filtration rate and albuminuria with all-cause mortality. Clin J Am Soc Nephrol. 2011; 6:2200–2207.
45. Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, Patel A, Cass A, Neal B, Poulter N, Mogensen CE, Cooper M, Marre M, Williams B, Hamet P, Mancia G, Woodward M, Macmahon S, Chalmers J. ADVANCE Collaborative Group. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 2009; 20:1813–1821.
46. Couchoud C, Villar E. End-stage renal disease epidemic in diabetics: is there light at the end of the tunnel? Nephrol Dial Transplant. 2013; 28:1073–1076.
47. Waanders F, Visser FW, Gans RO. Current concepts in the management of diabetic nephropathy. Neth J Med. 2013; 71:448–458.
48. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008; 358:580–591.
49. Esnault VL, Ekhlas A, Delcroix C, Moutel MG, Nguyen JM. Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. J Am Soc Nephrol. 2005; 16:474–481.
50. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension. 2003; 41:64–68.
51. Bjornstad P, Cherney D, Maahs DM. Early diabetic nephropathy in type 1 diabetes: new insights. Curr Opin Endocrinol Diabetes Obes. 2014; 21:279–286.
52. de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, Goldsberry A, Houser M, Krauth M, Lambers Heerspink HJ, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D, Chertow GM. BEACON Trial Investigators. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013; 369:2492–2503.
53. Mima A, Qi W, King GL. Implications of treatment that target protective mechanisms against diabetic nephropathy. Semin Nephrol. 2012; 32:471–478.
54. Chung S, Park CW. Role of peroxisome proliferator-activated receptor alpha in diabetic nephropathy. Diabetes Metab J. 2011; 35:327–336.
55. Fineberg D, Jandeleit-Dahm KA, Cooper ME. Diabetic nephropathy: diagnosis and treatment. Nat Rev Endocrinol. 2013; 9:713–723.
56. Higgins GC, Coughlan MT. Mitochondrial dysfunction and mitophagy: the beginning and end to diabetic nephropathy? Br J Pharmacol. 2014; 171:1917–1942.
57. Mima A. Inflammation and oxidative stress in diabetic nephropathy: new insights on its inhibition as new therapeutic targets. J Diabetes Res. 2013; 2013:248563.
Full Text Links
  • DMJ
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr